Karyopharm Therapeutics (NASDAQ:KPTI) Issues Earnings Results


Share on StockTwits

Karyopharm Therapeutics (NASDAQ:KPTI) issued its earnings results on Sunday. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.06), MarketWatch Earnings reports. Karyopharm Therapeutics had a negative return on equity of 187.66% and a negative net margin of 221.23%.

NASDAQ:KPTI traded down $0.96 on Tuesday, reaching $8.48. The stock had a trading volume of 3,723,849 shares, compared to its average volume of 2,442,094. The company has a market cap of $636.52 million, a price-to-earnings ratio of -2.92 and a beta of 0.93. Karyopharm Therapeutics has a 12-month low of $8.43 and a 12-month high of $21.82. The company has a debt-to-equity ratio of 1.38, a current ratio of 5.42 and a quick ratio of 5.39. The firm’s fifty day moving average is $10.35 and its two-hundred day moving average is $13.98.

Several research firms have issued reports on KPTI. SVB Leerink cut their price objective on Karyopharm Therapeutics from $22.00 to $15.00 and set an “outperform” rating for the company in a research report on Monday. Robert W. Baird cut their price target on shares of Karyopharm Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a report on Tuesday. Royal Bank of Canada reduced their price objective on shares of Karyopharm Therapeutics from $24.00 to $19.00 and set an “outperform” rating for the company in a research note on Tuesday. Zacks Investment Research lowered shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, February 18th. Finally, Barclays reduced their price target on shares of Karyopharm Therapeutics from $26.00 to $22.00 and set an “overweight” rating for the company in a research report on Friday, February 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $27.00.

In related news, insider Sharon Shacham sold 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 18th. The shares were sold at an average price of $12.39, for a total transaction of $49,560.00. Following the sale, the insider now owns 920,152 shares in the company, valued at $11,400,683.28. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders sold 14,681 shares of company stock valued at $207,959. Company insiders own 13.26% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1.

Recommended Story: Should I invest in “strong buy” stocks?

Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.